clinical trial
Aadi Bioscience Inks NGS Lab Partnerships to Screen Solid Tumor Patients for Fyarro Trial
The firm has partnered with Foundation Medicine, Tempus, and others to ID patients with TSC1 and TSC2 mutations for the Phase II PRECISION 1 clinical trial.
Stakeholders are working to harmonize strategies for overcoming the challenges faced by new blood-based multi-cancer early detection assays.
Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial
Pyramid will use Tempus' TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200.
Zentalis Pharmaceuticals, Caris Life Sciences Ink Precision Oncology Partnership
Caris will use its platform to sequence solid tumor patients' full exomes and transcriptomes to determine eligibility for Zentalis' Wee1 inhibitor ZN-c3.
Illumina, French Hospitals Partner on Cancer Genomic Profiling Study
The study will compare Illumina's TruSight Oncology 500 assay to the standard of care for therapy selection in up to 400 cancer patients.